Q-omics provides the consensus-scored NAT16 profile across patient tissues and cancer cell-line models. NAT16 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NAT16 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, NAT16 RNA expression shows 11,060 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where NAT16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAT16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAT16 survival associations across molecular data types. NAT16 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAT16 RNA expression–survival associations across cancer types. High NAT16 expression shows unfavorable associations in KIRC, BRCA, ACC, COAD, THCA and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NAT16 RNA expression.
This table summarizes NAT16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NAT16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAT16 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, LUAD, UCEC and BRCA. The COAD box plot shows higher NAT16 RNA expression in tumor versus normal tissue (log2 FC = +0.200, t-test p < 0.001).
This table shows molecular features associated with NAT16 in patient tissues and cancer cell lines. In patient samples, NAT16 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NAT16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
